Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream

Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board

Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14

Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF)

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream